Zobrazeno 1 - 10
of 1 526
pro vyhledávání: '"Pathologic Response"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background In locally advanced, operable esophageal squamous cell carcinoma (ESCC), neoadjuvant immunochemotherapy (nICT) has shown results that are somewhat comparable to those of standard neoadjuvant chemoradiotherapy (nCRT). The impact of
Externí odkaz:
https://doaj.org/article/d62ea1a408bf481c92f408bc53a0191f
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Objective To evaluate the potential utility of 18F-FDG PET/CT to assess response to neoadjuvant immunochemotherapy in patients with resectable NSCLC, and the ability to screen patients who may benefit from neoadjuvant immunochemotherapy. Met
Externí odkaz:
https://doaj.org/article/1f7dd2c58b5847c9a54c5bdebc7c290f
Autor:
Jianzhen Shan, Zhen Liu, Songan Chen, Chengli Du, Bing Li, Lingxiang Ruan, Mei Kong, Lingjie Wang, Miaoyan Du, Shuo Shi, Guoliang Qiao, Tian Tian, Zhengliang Tu
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background The standard care for resectable non-small cell lung cancer (NSCLC) involves perioperative therapy combining chemotherapy and immune checkpoint inhibitors, typically lasting 6 to 12 months. However, the optimal treatment strategie
Externí odkaz:
https://doaj.org/article/1df4da3fe6394c0eb462ca376ea036cf
Autor:
Lei Ji, Xi Chen, Xiaoyan Qian, Min Xiao, Qing Li, Qiao Li, Jiayu Wang, Ying Fan, Yang Luo, Shanshan Chen, Fei Ma, Binghe Xu, Pin Zhang
Publikováno v:
Breast, Vol 78, Iss , Pp 103792- (2024)
Background: The majority of HR+/HER2-breast cancer patients can also achieve long-term survival despite not attaining pCR, indicating limited prognostic value of pCR in this population. This study aimed to identify novel pathologic end points for pre
Externí odkaz:
https://doaj.org/article/b415375873c746b49f8af8289a695322
Autor:
Lyndsey Sandow, Liana Tsikitis, Charles D. Lopez, Brian Brinkerhoff, Adel Kardosh, Guillaume Pegna, Emerson Y. Chen
Publikováno v:
Clinical Case Reports, Vol 12, Iss 8, Pp n/a-n/a (2024)
Key Clinical Message Immunotherapy is considered first line in patients with dMMR metastatic colorectal cancer (CRC). Recent studies have also shown promising results with neoadjuvant immunotherapy in locally advanced CRC. We report a case in which n
Externí odkaz:
https://doaj.org/article/032aa4fc86644dd5ba3f6a3939f3a5eb
Autor:
Ali Emadi Torghabeh, Seyed Amir Aledavood, Ehsan Soltani, Mahsa Akbari Oryani, Saeed Akhlaghi, Sare Hosseini, Azar Fani Pakdel, Ali Taghizadeh Kermani, Kazem Anvari, Soodabeh Shahidsales, Shahrzad Bahadorian, Shervin Mashreghi Moghaddam
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveEsophageal cancer is a therapeutic challenge in most healthcare systems. Most patients present with locally advanced disease at diagnosis. Concurrent chemoradiotherapy (CRT) is the standard treatment for locally advanced esophageal carcinoma
Externí odkaz:
https://doaj.org/article/ae17bf46fcbb4b3e80ff5649e0f4cc88
Autor:
Ye Wang, Yingqiu Song, Runze Wang, Yu Wu, Mo Li, Ke Xu, Rong He, Zheng Wang, Qingqing Li, Feng-Ming (Spring) Kong, Tianlu Wang
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveMajor pathological response (MPR) helps evaluate the prognosis of patients with lung squamous cell carcinoma (LUSC). However, the clinical factors that affect the achievement of MPR after neoadjuvant chemoimmunotherapy (NCIO) in patients wit
Externí odkaz:
https://doaj.org/article/acf10aeacae24c94a1a2b12232390fa5
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-11 (2023)
Abstract Background Neoadjuvant chemotherapy (NAC) is widely used in the treatment of primary breast cancer. Different staging systems have been developed to evaluate the residual tumor after NAC and classify patients into different prognostic groups
Externí odkaz:
https://doaj.org/article/bb51aa5b47674cfeb0eb9c10331489f9
Publikováno v:
Breast, Vol 71, Iss , Pp 89-95 (2023)
The increasing use and effectiveness of primary systemic treatment (PST) enables tailored locoregional treatment. About one third of clinically node positive (cN+) breast cancer patients achieve pathologic complete response (pCR) of the axilla, with
Externí odkaz:
https://doaj.org/article/01eca1f60ed542ae9a36b20aef659ad4
Autor:
Gilles Houvenaeghel, Alexandre deNonneville, Monique Cohen, Laura Sabiani, Max Buttarelli, Emmanuelle Charaffe, Aurélie Jalaguier, Marie Bannier, Agnès Tallet, Frédéric Viret, Anthony Gonçalves
Publikováno v:
Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)
Abstract Aim We investigated the pathologic complete response rates (pCR) and survival outcomes of early breast cancer patients who underwent neoadjuvant chemotherapy (NAC) over 14 years at a French comprehensive cancer center and reported pCR and su
Externí odkaz:
https://doaj.org/article/45320565ca9343be958e19208d8fe6d4